Subcutaneous Opdivo improves cancer care by offering faster, accessible therapy, reducing time toxicity and expanding patient ...

Oncology nurses can educate patients on the benefits of subcutaneous administration, including reduced time in the infusion ...

The agency expects to issue a decision by Aug. 31, and it is slated to decide on maintenance dosing for an intravenous form of the drug later this month.

The subcutaneous autoinjector dosing, which would also take far less time than an infusion, would provide weekly maintenance for patients who have completed the biweekly intravenous initiation phase.

From foods that mimic the effects of Ozempic to energy-boosting injectables, these are the emerging health trends that will ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

IIT Bombay has developed needle-free shock syringes for painless, safe drug delivery, offering hope for a future without injection-related trauma. Tested on rats, it outperformed traditional needles ...

HYQVIA is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10% and one vial of Recombinant Human Hyaluronidase PH20 ...

The FDA has approved nivolumab and hyaluronidase-nvhy for subcutaneous injection in adults with solid tumors in which nivolumab is indicated, according to a press release. Nivolumab and ...

The FDA has approved the subcutaneous formulation of nivolumab (Opdivo). This approval makes it the first and only subcutaneously administered PD-1 inhibitor. Subcutaneous nivolumab is approved in all ...

At the center of this discovery stands a molecule called NAD, or nicotinamide adenine dinucleotide. The results have been published in Nature Metabolism. Professor Mathias Ziegler from the ...

In the center of this new discovery stands a molecule called NAD, or Nicotinamide Adenine Dinucleotide. Professor Mathias Ziegler from the Department of Biomedicine, University of Bergen (UiB ...